Cassava Sciences' Shares Down 46% After Adviser Is Indicted
By Josh Beckerman
Shares of Alzheimer's drug developer Cassava Sciences tumbled following the indictment of a medical professor who advised the company.
The stock fell 46% to $10.17. Cassava's shares fell at one point to $8.79 on Friday, the lowest they have been since October 2020. The shares are down 54% this year
The Justice Department said on Friday that City University of New York School of Medicine Professor Hoau-Yan Wang was indicted on charges related to obtaining federal research grants. It said he "allegedly engaged in a scheme to fabricate and alsify scientific data in grant applications."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 28, 2024 16:15 ET (20:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks